DESIGN OF THE SILENT CEREBRAL INFARCT TRANSFUSION (SIT) TRIAL

REFERENCES

• Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol. 2000;151:839–845.
   PubMed Web of Science ®Google Scholar
• Earley CJ, Kittner SJ, Feeser BR, Stroke in children and sickle-cell disease: Baltimore-Washington Cooperative Young Stroke Study. Neurology. 1998;51:169–176.
   PubMed Web of Science ®Google Scholar
• Ohene-Frempong K, Weiner SJ, Sleeper LA, Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–294.
   PubMed Web of Science ®Google Scholar
• Glauser TA, Siegel MJ, Lee BC, DeBaun MR. Accuracy of neurologic examination and history in detecting evidence of MRI-diagnosed cerebral infarctions in children with sickle cell hemoglobinopathy. J Child Neurol. 1995;10:88–92.
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Macklin EA, Moser FG, Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99:3014–3018.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Zimmerman RA, Pollock AN, Silent infarcts in young children with sickle cell disease. Br J Haematol. 2009;146:300–305.
   PubMed Web of Science ®Google Scholar
• Schatz J, Brown RT, Pascual JM, Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56:1109–1111.
   PubMed Web of Science ®Google Scholar
• Armstrong FD, Thompson RJ, Jr., Wang W, Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics. 1996;97:864–870.
   PubMed Web of Science ®Google Scholar
• Moran CJ, Siegel MJ, DeBaun MR. Sickle cell disease: imaging of cerebrovascular complications. Radiology. 1998;206:311–321.
   PubMed Web of Science ®Google Scholar
• Moser FG, Miller ST, Bello JA, The spectrum of brain MR abnormalities in sickle-cell disease: A report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol. 1996;17:965–972.
   PubMed Web of Science ®Google Scholar
• Baird RL, Weiss DL, Ferguson AD, Studies in sickle cell anemia: XXI. Clinico-pathological aspects of neurological manifestations. Pediatrics. 1964;34:92–100.
   Google Scholar
• King AA, Noetzel M, White DA, Blood transfusion therapy is feasible in a clinical trial setting in children with sickle cell disease and silent cerebral infarcts. Pediatr Blood Cancer. 2008;50:599–602.
   PubMedGoogle Scholar
• Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319:670–674.
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New Engl J Med. 1998;339:5–11.
   PubMed Web of Science ®Google Scholar
• Scothorn DJ, Price C, Schwartz D, Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr. 2002;140:348–354.
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Wang W, Granger S, Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Arch Neurol. 2001;58:2017–2021.
   PubMed Web of Science ®Google Scholar
• Landgraf JM. CHQ Manual. Boston: Health Act; 2000.
   Google Scholar
• Nixon SK, Maunsell E, Desmeules M, Mutual concurrent validity of the child health questionnaire and the health utilities index: an exploratory analysis using survivors of childhood cancer. Int J Cancer Suppl. 1999;12:95–105.
   PubMedGoogle Scholar
• Wechsler D. Wechsler Abbreviated Scale of Intelligence Manual. San Antonio: The Psychological Corporation; 1999.
   Google Scholar
• Wechsler D. Wechsler Pre-School and Primary Scale of Intelligence, WPPSI. New York: The Psychological Corporation; 1967.
   Google Scholar
• Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior Rating Inventory of Executive Function. Lutz: Psychological Assessment Resources; 2000.
   Google Scholar
• Raskino C, Pearson DA, Baker CJ, Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Pediatrics. 1999;104:e32.
   PubMed Web of Science ®Google Scholar
• Ryan C, Adams KM, Heaton RK, Grant I. Neurobehavioral assessment of medical patients in clinical trials: the DCCT experience. In: Mohr EBP, ed. Handbook of Clinical Trials: The Neurobehavioral Approach. Amsterdam/Lisse: Swets & Zeitlinger BV; 1991:215–242.
   Google Scholar
• Ichord R, Smith S, Garcia-Espana F, Pediatric adaptation of NIH stroke scale predicts outcome after arterial ischemic stroke in children. Stroke. 2005;36:480–481. (Abstract)
   Google Scholar
• Hurtig AL, White LS. Psychosocial adjustment in children and adolescents with sickle cell disease. J Pediatr Psychol. 1986;11:411–427.
   PubMed Web of Science ®Google Scholar
• Armitage P. Exclusions, losses to follow-Up, and withdrawals in clinical trials. In: Shapiro SLT, ed. Clinical Trials: Issues and Approaches. New York: Marcel Dekker; 1983:99–113.
   Google Scholar
• Buchanan GR, DeBaun MR, Quinn CT, Steinberg MH. Sickle cell disease. Hematology Am Soc Hematol Educ Program. 2004;35–47.
   PubMedGoogle Scholar
• Craft S, Schatz J, Glauser TA, Neuropsychologic effects of stroke in children with sickle cell anemia. J Pediatr. 1993;123:712–717.
   PubMed Web of Science ®Google Scholar